Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

Treatment-naive and relapsed/refractory MDS patients receiving venetoclax and HMAs have an ORR of 59% with 63% of responders proceeding to transplant. Allogeneic stem cell transplantation after treatment with venetoclax in combination with HMA is associated with prolonged survival.

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Ball, Brian J., Famulare, Christopher A., Stein, Eytan M., Tallman, Martin S., Derkach, Andriy, Roshal, Mikhail, Gill, Saar I., Manning, Benjamin M., Koprivnikar, Jamie, McCloskey, James, Testi, Rebecca, Prebet, Thomas, Al Ali, Najla H., Padron, Eric, Sallman, David A., Komrokji, Rami S., Goldberg, Aaron D.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2020
Matèries:
Stimulus Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7362378/
https://ncbi.nlm.nih.gov/pubmed/32589727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001482
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars